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1  | INTRODUC TION
Eslicarbazepine acetate (ESL) is a once‐daily antiepileptic drug (AED) 
that is approved in Europe as monotherapy in the treatment of focal‐
onset seizures, with or without secondary generalization, in adults 
with newly diagnosed epilepsy, and as adjunctive therapy in adults, 
adolescents, and children aged >6 years with focal‐onset seizures, 
with or without secondary generalization.1 ESL was approved for use 
as monotherapy in Europe on the basis of a phase III, randomized, 
double‐blind, non‐inferiority trial, in which once‐daily monotherapy 
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Abstract
Objectives: To assess the effectiveness and safety/tolerability of eslicarbazepine ac‐
etate (ESL) monotherapy in clinical practice in Europe.
Materials and methods: Euro‐Esli was a pooled analysis of 14 European clinical prac‐
tice	studies.	Responder	rate	(≥50%	seizure	frequency	reduction)	and	seizure	freedom	
rate (seizure freedom at least since prior visit) were assessed after 3, 6 and 12 months 
of ESL treatment and at last visit. Adverse events (AEs) and AEs leading to ESL dis‐
continuation were assessed throughout follow‐up. A subanalysis was conducted to 
assess outcomes for patients treated initially with ESL monotherapy and for patients 
treated at the last visit with ESL monotherapy.




with ESL monotherapy. Corresponding values for patients treated initially with ESL 
adjunctive	therapy	were	74.8%	and	39.0%,	respectively;	and	for	patients	treated	at	
the	 last	 visit	 with	 ESL	 adjunctive	 therapy,	 corresponding	 values	 were	 70.4%	 and	
25.9%,	 respectively.	 Safety	 and	 tolerability	were	generally	 comparable	 in	patients	
treated with ESL as monotherapy or adjunctive therapy. The most commonly re‐
ported	AEs	 (≥5%	of	patients	 in	any	group)	were	dizziness,	somnolence,	 instability/
ataxia, and fatigue.
Conclusions: These clinical practice data support the use of ESL as monotherapy, as 
well as adjunctive therapy, for focal‐onset seizures, complementing evidence from 
clinical trials.
K E Y W O R D S
adjunctive therapy, antiepileptic drug, clinical practice, eslicarbazepine acetate, Euro‐Esli, 
focal epilepsy, monotherapy
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with ESL was shown to be non‐inferior to twice‐daily monotherapy 
with controlled‐release carbamazepine.2 These findings are sup‐
ported by the results of two phase III withdrawal to monotherapy 
trials,3,4 which resulted in approval for ESL in the monotherapy set‐
ting in the United States.5
Clinical trials are essential for the development and approval of 
new AEDs, but due to the strict inclusion and exclusion criteria typ‐
ically employed, they may not always represent the entire breadth 
of patient types encountered in clinical practice.6,7 Furthermore, in‐
dividualized treatment approaches are used in clinical practice, and 
protocol‐defined dosing strategies may restrain assessment of this 
in clinical trials. Therefore, clinical practice studies complement evi‐
dence from clinical trials by further elucidating an agent’s effective‐
ness when used under everyday conditions.
The Euro‐Esli study addressed the need for clinical practice data 
by conducting an audit of clinical practice studies conducted across 
Europe, thereby providing insights into how the evidence obtained 
from ESL clinical trials has translated into the clinical practice set‐
ting.8 Euro‐Esli represents the largest study into the effectiveness 
of ESL in clinical practice to date, with over 2000 patients included 
in the study population,8 similar to the total number of patients re‐
cruited into ESL clinical trials (approximately 24001), and thereby 
providing strong evidence of how ESL performs in this setting. The 
size of the Euro‐Esli cohort has allowed meaningful, statistically ro‐
bust subanalyses to be conducted, providing further insights into the 
use of ESL in clinical practice.8
Since evidence for the use of ESL as monotherapy in clinical prac‐
tice is currently scarce, we present here the results of a subanalysis 
of data from patients included in Euro‐Esli who were either treated 
with ESL as initial monotherapy, or converted to ESL monotherapy 
after initially receiving ESL as adjunctive therapy.
2  | MATERIAL AND METHODS
2.1 | Study design
The Euro‐Esli study was an exploratory, retrospective, pooled analy‐
sis of data from European clinical practice studies,9‐21 conducted to 
audit the effectiveness, safety, and tolerability of ESL as an adjunc‐
tive treatment for focal‐onset seizures in clinical practice, details of 
which have been published previously.8 In brief, effectiveness was 
assessed after 3, 6, and 12 months of ESL treatment and at final fol‐
low‐up, and safety and tolerability were assessed for the duration 
of ESL treatment. The study protocol was approved by the Ethics 
Committee of Hospital Universitario y Politécnico La Fe, Valencia, 
Spain.8
A subanalysis was conducted of data from patients included in 
Euro‐Esli who were treated with ESL as initial monotherapy and 
patients who were being treated with ESL monotherapy at the last 
visit. Corresponding data were assessed for patients treated initially 
with ESL as adjunctive therapy and for those who were being treated 
with ESL as adjunctive therapy at the last visit. In addition, a fur‐
ther subanalysis of patients treated initially with ESL as adjunctive 
therapy was conducted, to compare outcomes for patients who sub‐
sequently	withdrew	to	ESL	monotherapy	with	those	who	continued	
to receive ESL as adjunctive therapy throughout follow‐up.
2.2 | Study population
The studies included in Euro‐Esli had broad inclusion/exclusion cri‐
teria, in order to be representative of the variety of patients encoun‐
tered in clinical practice.8 The current analysis included all patients 
from Euro‐Esli for whom the number of AEDs used initially and at 
the last visit was known.
2.3 | Study assessments
Effectiveness was evaluated by assessing responder and seizure 
freedom	 rates.	 Response	was	 defined	 as	 ≥50%	 seizure	 frequency	
reduction from baseline (ie, prior to ESL initiation), and seizure free‐
dom was defined as having no seizures since at least the prior visit 
(either 3 or 6 months, depending on the time point at which seizure 
freedom was assessed).
Safety and tolerability were assessed by the evaluation of ad‐
verse events (AEs) and rate of ESL discontinuation due to AEs, re‐
spectively. AEs of special interest (hyponatremia and rash) were 
specifically evaluated. AEs (including hyponatremia and rash) were 
classified by participating clinicians according to Medical Dictionary 
for Regulatory Activities definitions. Sodium levels were evaluated, 
when recorded.
2.4 | Statistical analyses
Details of the statistical methodology employed in Euro‐Esli have 
been published previously.8 The safety population was defined as all 
patients who initiated ESL treatment and the effectiveness popula‐
tion was defined as all patients who initiated ESL treatment and had 
at least one effectiveness assessment. There was great heterogene‐
ity in the particular objectives of the studies included in the analy‐
sis and, thus, in the information each study reported. The current 
analysis attempted to combine the reported information in the most 
complete way possible. Missing data were not imputed, except in 
cross‐sectional studies, in which the last visit data were captured 
and included in the established cutoff points (3, 6, or 12 months). 
When the observation timepoint of a study did not match the es‐
tablished cutoff points, the following allocations were made: ob‐
servations performed between 1.5 and <4.5 months were allocated 
to the 3‐month visit; those performed between 4.5 and <9 months 
were allocated to the 6‐month visit; and those performed between 
9 and 15 months were allocated to the 12‐month visit. A “final” vari‐
able was also created, in which the last observation of each patient 
was included, independently of the timepoint when it occurred. 
Since this was an exploratory study, no hypothesis was defined. No 
systematic review of the individual patients was undertaken due to 
the heterogeneity of the individual samples and objectives of each 
study. Therefore, individual studies were not treated as clusters.8
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A	 descriptive	 analysis	 of	 quantitative	 and	 qualitative	 variables	
was performed.8 For each variable, the total number of patients for 
whom	the	data	in	question	were	available	was	stated	and	this	value	
was used as the denominator for analysis. Quantitative variables 
were described as mean, standard deviation (SD), median, minimum 
and maximum values, together with the number of valid cases and 
confidence	 intervals	 (CIs)	 or	 interquartile	 range	 (25th	 percentile	
to 75th percentile). Qualitative variables (responder rate, seizure 
freedom rate, incidence of AEs, rate of discontinuation due to AEs) 
were	described	as	means	of	absolute	frequencies	and	percentages.	
In the sub‐analysis of patients who were initially treated with ESL 
as adjunctive therapy, demographic and baseline characteristics 
were compared between the subgroups of patients who withdrew 
to ESL monotherapy versus those who continued to receive ESL as 
adjunctive therapy using the Student’s t test, Mann–Whitney U test, 
or	chi‐squared	test,	as	appropriate.	ESL	dosing	levels	were	similarly	
compared using the Mann–Whitney U test. Duration of ESL treat‐
ment was assessed using Kaplan‐Meier analysis and compared be‐
tween the subgroups of patients who did versus did not withdraw to 
ESL monotherapy using the log‐rank test. Effectiveness, safety, and 
tolerability assessments were compared between the subgroups of 
patients who did versus did not withdraw to ESL monotherapy using 
the	chi‐squared	test.	The	Statistical	Package	for	the	Social	Sciences	
version 19.0 was used for all analyses, and the significance level was 
5%.8
3  | RESULTS
Euro‐Esli included a total of 2058 patients from 14 European clini‐
cal practice studies.8 These studies included patients treated with 
ESL between November 2009 and December 2016. The number 
of initial AEDs patients were receiving at study entry was known 
for	2045	patients,	of	whom	88	(4.3%)	received	ESL	as	initial	mono‐
therapy. The number of previous AEDs received was known for 49 
of	these	88	patients,	of	whom	17	(34.7%)	had	not	been	treated	with	
another AED prior to starting ESL monotherapy. The number of 
AEDs patients were receiving at the last visit was known for 1340 
patients,	of	whom	229	(17.1%)	were	being	treated	with	ESL	mono‐
therapy. These included patients treated with ESL as initial mono‐
therapy and those who converted to ESL monotherapy after initially 
receiving ESL as adjunctive therapy.
Of the 1957 patients who received ESL as initial adjunctive ther‐
apy,	information	on	whether	or	not	patients	subsequently	withdrew	
to ESL monotherapy was known for 1309 patients, of whom 199 
(15.2%)	withdrew	to	ESL	monotherapy	and	1110	(84.8%)	continued	
to receive ESL as adjunctive therapy.
3.1 | Study population
Demographic and baseline characteristics of patients who received 
ESL as initial monotherapy and monotherapy at the last visit are 
summarized in Table 1, together with the corresponding data for 
patients treated with ESL as initial adjunctive therapy and adjunctive 
therapy at the last visit. For the subanalysis of patients who were 
treated with ESL as initial adjunctive therapy, corresponding data for 
those	who	did	versus	did	not	subsequently	withdraw	to	ESL	mono‐
therapy are presented in Table 2, together with results of statistical 
comparisons.
Several of the baseline characteristics of patients who received 
ESL as initial monotherapy differed from those of patients who re‐
ceived ESL as initial adjunctive therapy (Table 1). Age at onset of 
epilepsy was higher for patients who received ESL as initial mono‐
therapy versus initial adjunctive therapy (mean [SD] age at onset, 
27.9 [18.6] vs 23.1 [19.2] years), and duration of epilepsy was shorter 
(mean [SD] duration, 13.4 [15.2] vs 21.2 [16.3] years). In addition, 
the	baseline	frequency	of	partial	seizures	was	lower	in	patients	who	
received ESL as initial monotherapy versus initial adjunctive ther‐
apy	 (mean	 [SD]	monthly	 frequency,	 5.2	 [12.4]	 vs	13.9	 [50.7]).	 The	
proportion of patients with psychiatric comorbidity was higher in 
patients who received ESL as initial monotherapy versus initial ad‐
junctive	therapy	(46.7%	vs	24.3%).
Similarly, there were differences in a number of demographic 
and baseline characteristics between patients who received ESL as 
monotherapy at the last visit, compared with those who received 
ESL as adjunctive therapy at the last visit (Table 1). The proportion 
of male‐to‐female patients differed between groups (percentage of 
male	patients,	59.8%	for	patients	who	received	ESL	as	monotherapy	
vs	50.3%	for	patients	who	received	ESL	as	adjunctive	therapy).	The	
age of patients was higher for patients treated with ESL as mono‐
therapy versus adjunctive therapy at the last visit (mean [SD] age, 
46.4 [18.7] vs 43.4 [15.2] years). The age of patients at onset of 
epilepsy was also higher for patients who received ESL as mono‐
therapy versus adjunctive therapy at the last visit (mean [SD] age at 
onset, 34.3 [22.5] vs 21.5 [18.3] years), and the duration of epilepsy 
was shorter (mean [SD] duration, 12.3 [14.8] vs 21.9 [16.7] years). 
Monthly	seizure	frequencies	were	lower	for	patients	who	received	
ESL as monotherapy versus adjunctive therapy at the last visit, for 
any type of partial seizure and across partial seizure subtypes. The 
number of previous AEDs used was fewer in patients who received 
ESL as monotherapy versus adjunctive therapy at the last visit (mean 
[SD] number of previous AEDs, 1.5 [1.2] vs 4.1 [3.5]), and the pro‐
portion	of	patients	with	psychiatric	comorbidity	was	higher	(28.6%	
vs	18.9%).
In the subanalysis of patients who were treated with ESL as ini‐
tial adjunctive therapy, there were significant differences in demo‐
graphic and baseline characteristics between patients who withdrew 
to ESL monotherapy compared with those who received ESL as ad‐
junctive therapy throughout follow‐up (Table 2). Patients who with‐
drew to monotherapy were older than those who did not (mean [SD] 
age, 47.2 [18.6] vs 43.4 [15.2]; P = 0.006) and a greater proportion of 
patients who withdrew to monotherapy were male compared with 
those	who	did	not	(60.8%	vs	50.2%;	P = 0.006). In addition, patients 
who withdrew to monotherapy, compared with those who did not, 
had a later onset of epilepsy (mean [SD] age at onset, 34.3 [22.8] vs 
21.4 [18.3] years; P < 0.001), shorter duration of epilepsy (mean [SD] 
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TA B L E  1   Patient demographics and baseline characteristics of patients treated with ESL as initial monotherapy, ESL as monotherapy at 
the last visit, ESL as initial adjunctive therapy and ESL as adjunctive therapy at the last visit
ESL as initial 
monotherapy
ESL as monotherapy at last 
visit
ESL as initial adjunctive 
therapy
ESL as adjunctive 
therapy at last visit
Baseline demographics
Sex
Na 88 229 1956 1110
Male,	n	(%) 41 (46.6) 137 (59.8) 1022 (52.2) 558 (50.3)
Female,	n	(%) 47 (53.4) 92 (40.2) 934 (47.8) 552 (49.7)
Age
Na 88 229 1956 1110
Mean (SD), years 41.2 (15.7) 46.4 (18.7) 44.2 (15.5) 43.4 (15.2)
Median (range), 
years
40.5 (14‐79) 46.0 (14.0‐87.0) 43.0 (14‐88) 41.4 (15.0‐88.0)
Epilepsy‐related characteristics
Age at onset of epilepsy
Na 76 221 1782 1067
Mean (SD), years 27.9 (18.6) 34.3 (22.5) 23.1 (19.2) 21.5 (18.3)
Median (range), 
years
23.5 (0‐76) 28.0 (0‐87) 18.0 (0‐87) 17.0 (0‐87)
Duration of epilepsy
Na 76 221 1782 1067
Mean (SD), years 13.4 (15.2) 12.3 (14.8) 21.2 (16.3) 21.9 (16.7)
Median (range), 
years
7.5 (0.0‐70.0) 7.0 (0.0‐70.5) 19.0 (0.0‐81.8) 19.0 (0.0‐81.8)
Etiologyb
Na 81 205 1574 873
Structural‐meta‐
bolic,	n	(%)
35 (43.2) 111 (54.1) 911 (57.9) 483 (55.3)
Genetic,	n	(%) 4 (4.9) 3 (1.5) 32 (2.0) 17 (1.9)
Unknown,	n	(%) 42 (51.9) 91 (44.4) 631 (40.1) 373 (42.7)
Baseline seizure type
Any partial seizure
Na 83 227 1897 1098
Yes,	n	(%) 57 (68.7) 193 (85.0) 1787 (94.2) 1082 (98.5)
Simple partial seizures
Na 83 222 1747 1098
Yes,	n	(%) 13 (15.7) 59 (26.6) 464 (26.6) 329 (30.0)
Complex partial seizures
Na 83 222 1747 1098
Yes,	n	(%) 30 (36.1) 85 (38.3) 1106 (63.3) 761 (69.3)
Secondarily generalized seizures
Na 83 222 1747 1098
Yes,	n	(%) 26 (31.3) 87 (39.2) 759 (43.4) 443 (40.3)
Baseline	monthly	seizure	frequency
Any partial seizure
Na 55 193 1787 1076
Mean (SD) 5.2 (12.4) 4.6 (20.6) 13.9 (50.7) 13.9 (50.4)
(Continues)
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duration, 13.1 [15.3] vs 21.9 [16.6] years; P < 0.001), lower baseline 
seizure	frequency	across	all	seizure	types	(P	≤	0.001	for	all	compar‐
isons), and had been treated with fewer previous AEDs (mean [SD] 
number of previous AEDs, 1.4 [1.1] vs 4.1 [3.5]; P < 0.001). The pro‐
portion of patients with psychiatric comorbidity was also higher in 
patients who withdrew to monotherapy compared with those who 
did	not	(26.4%	vs	18.9%;	P = 0.035).
3.2 | ESL treatment
In the majority of patients, ESL was initiated due to lack of effective‐
ness of previous treatment and/or adverse reaction(s) to previous 
treatment (Table 1). In the subanalysis of patients treated with ESL as 
initial adjunctive therapy, there was a significant difference between 
patients who did versus did not withdraw to ESL monotherapy in 
ESL as initial 
monotherapy
ESL as monotherapy at last 
visit
ESL as initial adjunctive 
therapy
ESL as adjunctive 
therapy at last visit
Median (range) 1.3 (0.3‐66.7) 1.0 (0.1‐240.0) 3.0 (0.1‐1230.0) 3.3 (0.1‐1230.0)
Simple partial seizures
Na 9 55 386 298
Mean (SD) 12.3 (19.9) 6.8 (20.8) 14.7 (60.4) 10.9 (23.3)
Median (range) 1.0 (0.3‐60.0) 1.5 (0.3‐150.0) 3.0 (0.3‐900.0) 3.1 (0.3‐210.0)
Complex partial seizures
Na 25 81 954 704
Mean (SD) 5.2 (9.7) 5.6 (26.6) 8.4 (22.4) 8.3 (22.1)
Median (range) 1.3 (0.3‐40.0) 1.5 (0.3‐240.0) 2.9 (0.2‐300.0) 3.0 (0.3‐300.0)
Secondarily generalized seizures
Na 22 83 604 379
Mean (SD) 1.1 (0.8) 0.6 (0.5) 2.6 (6.3) 3.0 (7.1)
Median (range) 1.0 (0.3‐4.0) 0.3 (0.2‐3.3) 0.9 (0.1‐70.0) 1.0 (0.2‐70.0)
Comorbidities
Intellectual disability
Na 32 48 918 511
Yes,	n	(%) 4 (12.5) 3 (6.3) 104 (11.3) 51 (10.0)
Psychiatric comorbidityc
Na 30 175 1106 635
Yes,	n	(%) 14 (46.7) 50 (28.6) 269 (24.3) 120 (18.9)
Depression
Na 30 175 1102 635
Yes,	n	(%) 6 (20.0) 19 (10.9) 135 (12.3) 59 (9.3)
AED treatment
Total number of previous AEDs
Na 49 220 1837 1088
Mean (SD) 1.8 (2.2) 1.5 (1.2) 4.1 (3.4) 4.1 (3.5)
Median (range) 1.0 (0‐9) 1.0 (0‐10) 3.0 (0‐20) 3.0 (0‐20)
Reason for ESL treatment initiation
Na 8 196 1309 813
Lack of effective‐
ness,	n	(%)
2 (25.0) 81 (41.3) 972 (74.3) 658 (80.9)
Adverse reaction, n 
(%)
1 (12.5) 81 (41.3) 184 (14.1) 58 (7.1)
Both,	n	(%) 3 (37.5) 17 (8.7) 109 (8.3) 87 (10.7)
Other,	n	(%) 2 (25.0) 17 (8.7) 44 (3.4) 10 (1.2)
AED, antiepileptic drug; ESL, eslicarbazepine acetate; SD, standard deviation.
aTotal	number	of	patients	for	whom	data	in	question	were	available.	
bInternational League Against Epilepsy 2010 classification. 
cIncluding depression. 
TA B L E  1   (Continued)
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the reasons for initiating ESL treatment (Table 2; P < 0.001), primar‐
ily because a higher proportion of patients who withdrew to ESL 
monotherapy, compared with those who did not, initiated ESL treat‐
ment	 due	 to	 adverse	 reaction(s)	 to	 previous	 treatment	 (42.0%	 vs	
7.1%)	and	a	lower	proportion	initiated	ESL	due	to	lack	of	effective‐
ness	of	previous	treatment	(41.5%	vs	80.9%).	Details	of	ESL	dosing	
during the course of follow‐up are summarized in Table 3. The mean 
(SD) ESL dose at baseline was 800.0 (253.0) mg/day (median, 800; 
range, 400‐1200) in patients treated with ESL as initial monotherapy 
and 527.0 (247.7) mg/day (median, 400; range, 150‐1600) in patients 
treated with ESL as initial adjunctive therapy. The mean (SD) ESL 
dose at the last visit was 878.9 (275.9) mg/day (median, 800; range, 
400‐2400) in patients treated with ESL as monotherapy at the last 
visit and 962.2 (315.7) mg/day (median, 800; range, 200‐2800) in 
patients treated with ESL as adjunctive therapy at the last visit.
The	 mean	 duration	 of	 ESL	 treatment	 was	 36.8	months	 (95%	
confidence interval [CI], 33.5‐40.0) in patients who received ESL as 
initial	monotherapy	and	27.9	months	(95%	CI,	27.0‐28.8)	in	patients	
who received ESL as monotherapy at the last visit. The proportions 
of patients who discontinued ESL treatment during follow‐up were 
18.1%	 (15/83)	 for	 those	who	 received	 ESL	 as	 initial	monotherapy	
and	8.8%	(20/228)	for	those	who	received	ESL	as	monotherapy	at	
the last visit. Among patients who received ESL as initial monother‐
apy,	reasons	for	ESL	discontinuation	were	AEs	(9.6%;	n	=	8),	lack	of	
efficacy	(3.6%;	n	=	3),	other	(3.6%;	n	=	3),	and	unknown	(1.2%;	n	=	1).	





44.2‐54.3) in patients who received ESL as initial adjunctive ther‐
apy	and	34.7	months	(95%	CI,	30.9‐38.6)	in	those	who	received	ESL	
as adjunctive therapy at the last visit. The proportions of patients 
who	 discontinued	 ESL	 treatment	 during	 follow‐up	 were	 26.6%	
(512/1924) for those who received ESL as initial adjunctive therapy 
and	 25.4%	 (280/1104)	 for	 those	 who	 received	 ESL	 as	 adjunctive	
therapy at the last visit. Among patients who received ESL as initial 
adjunctive therapy, reasons for ESL discontinuation comprised AEs 
(10.1%;	n	=	195),	lack	of	efficacy	(8.0%;	n	=	154),	AEs	and	lack	of	ef‐
ficacy	 (3.3%;	n	=	64),	other	 (2.2%;	n	=	42	 [most	commonly,	patient	
decision	(n	=	9)	and	lack	of	compliance	(n	=	3)])	and	unknown	(3.0%;	






Responder rates in patients who received ESL as initial monotherapy 
were	94.1%	(48/51)	at	12	months	and	76.3%	(58/76)	at	the	last	visit	
(Figure 1A). The corresponding responder rates in patients who re‐
ceived	ESL	as	monotherapy	at	 the	 last	visit	were	93.2%	 (177/190)	
and	90.4%	(206/228),	respectively	(Figure	1B).	At	all	timepoints,	re‐
sponder rates were lower in patients who received ESL as adjunctive 
therapy than in those who received ESL as monotherapy: responder 
rates in patients who received ESL as initial adjunctive therapy 
were	 74.8%	 (748/1000)	 at	 12	months	 and	 63.1%	 (1136/1800)	 at	
the last visit (Figure 1C), and the corresponding values for patients 
who	received	ESL	as	adjunctive	therapy	at	the	last	visit	were	70.4%	
(421/598)	and	63.4%	(684/1079),	respectively	(Figure	1D).
Seizure freedom rates in patients who received ESL as initial 
monotherapy	were	 88.2%	 (45/51)	 at	 12	months	 and	 59.0%	 (49/83)	
at the last visit (Figure 1A). The corresponding seizure freedom rates 
in patients who received ESL as monotherapy at the last visit were 
77.4%	(147/190)	and	70.2%	(160/228),	respectively	(Figure	1B).	At	all	
timepoints, seizure freedom rates were lower in patients who received 
ESL as adjunctive therapy than in those who received ESL as mono‐
therapy: seizure freedom rates in patients who received ESL as initial 
adjunctive	therapy	were	39.0%	(390/1000)	at	12	months	and	31.3%	
(589/1879) at the last visit (Figure 1C), and the corresponding values 
for patients who received ESL as adjunctive therapy at the last visit 
were	25.9%	(155/598)	and	26.1%	(283/1085),	respectively	(Figure	1D).
In the subanalysis of patients who received ESL as initial adjunc‐
tive therapy, responder and seizure freedom rates were significantly 
higher in patients who withdrew to monotherapy compared with 
those who received ESL as adjunctive therapy throughout follow‐up, 
at all timepoints (P < 0.001 for all comparisons; Figure 2).
3.4 | Safety and tolerability
A summary of AEs and AEs leading to discontinuation is presented in 
Table 4. The overall incidence of AEs was similar in patients treated 
with ESL as initial monotherapy and patients treated with ESL mon‐
otherapy	at	 the	 last	visit	 (29.4%	 [25/85]	and	27.1%	 [62/229]).	The	
rate of ESL discontinuation due to AEs was higher in patients treated 
with ESL as initial monotherapy than in those treated with ESL as 
monotherapy	at	the	last	visit	(9.8%	[8/82]	and	4.8%	[11/228]).
The overall incidence of AEs was similar in patients treated 
with ESL as initial adjunctive therapy and those treated with ESL 
as	adjunctive	therapy	at	the	last	visit	(34.4%	[665/1933]	and	30.8%	
[342/1109]). The rate of ESL discontinuation due to AEs was also 
similar in patients treated with ESL as initial adjunctive therapy and 
those	 treated	with	 ESL	 adjunctive	 therapy	 at	 the	 last	 visit	 (13.9%	
[259/1867]	and	14.4%	[158/1096]).
The	most	commonly	reported	AEs	(≥5%	of	patients	in	any	group)	
were dizziness, somnolence, instability/ataxia and fatigue, and the 
most	 commonly	 reported	 AEs	 leading	 to	 discontinuation	 (≥2%	 of	
patients in any group) were dizziness and fatigue. In patients who 
received ESL as monotherapy, either as initial treatment or at the 
last	visit,	no	individual	AE	led	to	discontinuation	of	≥2%	of	patients.
The incidences of hyponatremia and rash were low, although, 
in general, slightly higher in patients who received ESL as adjunc‐
tive therapy versus monotherapy (Table 4). Similarly, hyponatremia 
and	rash	led	to	discontinuation	of	a	low	proportion	of	patients	(<2%	
across subgroups), although the rates of discontinuation were higher 
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TA B L E  2   Patient demographics and baseline characteristics of patients treated with ESL as initial adjunctive therapy who did and did not 
subsequently	withdraw	to	ESL	monotherapy
Withdrawal from ESL 
adjunctive therapy to ESL 
monotherapy




Nb 199 1109 0.006c
Male,	n	(%) 121 (60.8) 557 (50.2)
Female,	n	(%) 78 (39.2) 552 (49.8)
Age
Nb 199 1109 0.006d
Mean (SD), years 47.2 (18.6) 43.4 (15.2)
Median (range), years 47.0 (17.0‐87.0) 41.3 (15.0‐88.0)
Epilepsy‐related characteristics
Age at onset of epilepsy
Nb 198 1066 <0.001e
Mean (SD), years 34.3 (22.8) 21.4 (18.3)
Median (range), years 28.0 (0.0‐87.0) 17.0 (0.0‐87.0)
Duration of epilepsy
Nb 198 1066 <0.001e
Mean (SD), years 13.1 (15.3) 21.9 (16.6)
Median (range), years 8.0 (0.0‐70.5) 19.0 (0.0‐81.8)
Etiologyf
Nb 176 872 NSc
Structural‐metabolic, n 
(%)
99 (56.3) 482 (55.3)
Genetic,	n	(%) 3 (1.7) 17 (1.9)
Unknown,	n	(%) 74 (42.0) 373 (42.8)
Baseline seizure type
Any partial seizure
Nb 199 1097 <0.001c
Yes,	n	(%) 167 (83.9) 1081 (98.5)
Simple partial seizures
Nb 192 1097 NSc
Yes,	n	(%) 50 (26.0) 329 (30.0)
Complex partial seizures
Nb 192 1097 <0.001c
Yes,	n	(%) 73 (38.0) 760 (69.3)
Secondarily generalized seizures
Nb 192 1097 NSc
Yes,	n	(%) 73 (38.0) 443 (40.4)
Baseline	monthly	seizure	frequency
Any partial seizure
Nb 167 1075 <0.001e
Mean (SD) 4.9 (22.2) 13.9 (50.4)
Median (range 1.0 (0.1‐240.0) 3.3 (0.1‐1230.0)
Simple partial seizures
(Continues)
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with adjunctive therapy than with monotherapy. Hyponatremia was 
reported in 68 patients in the total Euro‐Esli population. Sodium 
levels were recorded for 52 of these patients, among whom the 
mean	(SD)	sodium	level	was	127.3	(4.5)	mEq/L	(median,	127.0;	range,	
117‐137).	 A	 total	 of	 15	 patients	 had	 sodium	 levels	 <125	mEq/L	
recorded (range, 116‐124 mEg/L). None of the patients treated with 
ESL as initial monotherapy or ESL monotherapy at the last visit had 
sodium	levels	<125	mEq/L	recorded.	One	(1.2%)	patient	treated	with	
ESL as initial monotherapy and none of the patients treated with 
ESL monotherapy at the last visit developed rash. Rash developed 
Withdrawal from ESL 
adjunctive therapy to ESL 
monotherapy
ESL adjunctive therapy throughout 
follow‐up P‐valuea
Nb 49 298 0.001e
Mean (SD) 7.2 (22.0) 10.9 (23.3)
Median (range) 1.7 (0.3‐150.0) 3.1 (0.3‐210.0)
Complex partial seizures
Nb 71 703 0.001e
Mean (SD) 6.2 (28.4) 8.3 (22.1)
Median (range) 1.7 (0.3‐240.0) 3.0 (0.3‐300.0)
Secondarily generalized seizures
Nb 71 379 <0.001e
Mean (SD) 0.6 (0.5) 3.0 (7.1)
Median (range) 0.3 (0.2‐3.3) 1.0 (0.2‐70.0)
Comorbidities
Intellectual disability
Nb 32 511 NSc
Yes,	n	(%) 1 (3.1) 51 (10.0)
Psychiatric comorbidityg
Nb 159 635 0.035c
Yes,	n	(%) 42 (26.4) 120 (18.9)
Depression
Nb 159 635 NSc
Yes,	n	(%) 15 (9.4) 59 (9.3)
AED treatment
Total number of previous AEDs
Nb 191 1087 <0.001e
Mean (SD) 1.4 (1.1) 4.1 (3.5)
Median (range) 1.0 (0‐10) 3.0 (0‐20)
Reason for ESL treatment initiation
Nb 193 812 <0.001c
Lack of effectiveness, n 
(%)
80 (41.5) 657 (80.9)
Adverse	reaction,	n	(%) 81 (42.0) 58 (7.1)
Both,	n	(%) 16 (8.3) 87 (10.7)
Other,	n	(%) 16 (8.3) 10 (1.2)
AED, antiepileptic drug; ESL, eslicarbazepine acetate; NM, not measured; NS, not significant; SD, standard deviation.
aWithdrawal to ESL monotherapy versus ESL as adjunctive therapy throughout follow‐up. 
bTotal	number	of	patients	for	whom	data	in	question	were	available.	
cChi‐squared	test.	
dStudent’s t test. 
eMann–Whitney U test. 
fInternational League Against Epilepsy 2010 classification. 
gIncluding depression. 
TA B L E  2   (Continued)




In the subanalysis of patients who received ESL as initial ad‐
junctive therapy, the overall incidence of AEs was similar in patients 
who withdrew to ESL monotherapy and those who received ESL 
adjunctive	therapy	throughout	follow‐up	(28.6%	[57/199]	vs	30.9%	
[342/1108]; χ2 = 0.39; P = not significant). However, the rate of ESL 
discontinuation due to AEs was significantly lower in patients who 
withdrew to ESL monotherapy compared with those who received 
ESL	adjunctive	therapy	throughout	follow‐up	(4.5%	[9/199]	vs	14.4%	
[158/1095]; χ2 = 14.70; P < 0.001).
4  | DISCUSSION
Euro‐Esli is the largest ESL clinical practice study conducted to date.8 
The findings of this subanalysis of Euro‐Esli data demonstrate that 
ESL monotherapy was effective when used under everyday clinical 
practice conditions in Europe. Responder and seizure freedom rates 
were higher in patients treated with ESL as monotherapy than in 
those treated with ESL as adjunctive therapy. The safety and toler‐
ability of ESL were generally comparable in patients treated with ESL 
as monotherapy or adjunctive therapy.
The higher responder and seizure freedom rates observed in 
patients treated with monotherapy in comparison with adjunctive 
therapy are likely to have been because patients on monotherapy 
were less refractory to treatment and/or had less severe epilepsy 
than	those	who	required	adjunctive	therapy.	For	example,	subanaly‐
sis of patients who received ESL as initial adjunctive therapy demon‐
strated	 that	 those	 who	 subsequently	 withdrew	 to	 monotherapy,	
compared with those who received ESL adjunctive therapy through‐
out follow‐up, had a significantly later onset of epilepsy, shorter 
duration	 of	 epilepsy,	 and	 lower	 baseline	 seizure	 frequency	 across	
all seizure types, and had been treated with significantly fewer pre‐
vious AEDs. Similar patterns of difference were observed between 
patients who received ESL as initial monotherapy and those who 
received ESL as initial adjunctive therapy, and between patients 
who received ESL as monotherapy at the last visit and those who 
received ESL as adjunctive therapy at the last visit. Taken together, 
these findings appear to support the notion that patients treated 
with ESL monotherapy were either less refractory to treatment and/
or had less severe epilepsy, or were being treated earlier in their 
disease course, than those who received ESL as adjunctive therapy. 
This hypothesis is supported by the findings of a previous subanaly‐
sis of Euro‐Esli data, which demonstrated that responder and seizure 
rates were higher in patients treated with less than two versus two 
or more concomitant AEDs, where the number of concomitant AEDs 
was employed as a marker for treatment refractoriness.8 It is also 
notable that the incidence of psychiatric comorbidity at baseline was 
higher in patients who received ESL as monotherapy than in those 
who received ESL as adjunctive therapy. Although the reasons for 
this are unclear, it might be hypothesized that clinicians specifically 
chose ESL as monotherapy for patients with psychiatric comorbidity, 
since it is associated with fewer psychiatric side effects than some 
other AEDs (eg, levetiracetam, topiramate, valproate).1,22‐24
In terms of ESL dosing, it is important to point out that baseline 
dose levels used for ESL monotherapy and adjunctive therapy were 
only accurate for those patients initiating treatment with monother‐
apy and adjunctive therapy (since some patients treated with ESL as 
initial	monotherapy	would	have	subsequently	received	concomitant	
AED treatment and some of those treated with ESL as initial ad‐
junctive	therapy	would	have	subsequently	withdrawn	to	ESL	mono‐
therapy). Likewise, the ESL dose levels used as monotherapy and 
adjunctive therapy at the last visit were only accurate for the sub‐
groups of patients who received ESL as monotherapy and adjunctive 
therapy at the last visit. Taking these factors into consideration, the 
mean (SD) dose of ESL used as monotherapy increased from 800.0 
(253.0) mg/day at baseline to 878.9 (275.9) mg/day at the last visit, 
and the mean (SD) dose of ESL used as adjunctive therapy increased 
from 527.0 (247.7) mg/day at baseline to 962.2 (315.7) mg/day at 
the last visit. The relatively small increase in mean ESL dose when 
used as monotherapy, in comparison with adjunctive therapy, is 
likely to reflect the relatively high responder and seizure freedom 
rates observed in patients treated with ESL as monotherapy in com‐
parison with adjunctive therapy, since patients experiencing inade‐
quate	seizure	control	were	likely	to	have	had	their	dosing	increased.	
Tolerability is also generally better in the monotherapy setting, com‐
pared with the adjunctive therapy setting, regardless of the initial 
dosage. Therefore, patients treated with ESL as initial monotherapy 
may have been started on a higher dosage in order to reach thera‐
peutic levels as soon as possible and/or because clinicians preferred 
to start treatment immediately at a therapeutic dosage (800 mg/
day) and avoid titration. The duration of ESL treatment was shorter 
in patients who received monotherapy than in those who received 
adjunctive therapy. This is likely to be because the first patients in‐
cluded in this study were treated with ESL as adjunctive therapy (as 
happens with all AEDs), and there was a delay before ESL became 
consolidated as a viable treatment option as clinicians gained experi‐
ence	with	the	drug	and	subsequently	started	to	use	it	as	monother‐
apy. Furthermore, patients who are relatively early in their disease 
course (with a relatively short duration of treatment) are less likely 
to have relapsed than those with more long‐standing epilepsy (with 
a longer duration of treatment), and are therefore more likely to be 
on monotherapy. The proportion of patients who discontinued ESL 
was also lower in patients who received ESL as monotherapy than 
in those who received ESL as adjunctive therapy, primarily because 
a higher proportion of patients treated with ESL as adjunctive ther‐
apy discontinued due to lack of efficacy. These findings again sup‐
port the idea that patients who received ESL as adjunctive therapy 
were more refractory to treatment than those treated with ESL as 
monotherapy.
The proportion of patients treated with ESL as monotherapy 
increased	from	4.3%	at	baseline	to	17.1%	at	the	last	visit,	consistent	
with the significant reduction in the number of concomitant AEDs 
patients used at the last visit, compared with baseline, previously 
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reported for the overall Euro‐Esli population.8 The decrease in use 
of concomitant AEDs and associated increase in the proportion 
of patients treated with monotherapy following ESL initiation are 
encouraging, since it is recommended that polytherapy levels be 
reduced wherever possible, due to the potentially increased risk 
of pharmacokinetic interactions and toxicity associated with an 
increased drug burden.25‐27 The study’s findings appear to sup‐
port the value of such a recommendation, because although the 
incidence of AEs was similar regardless of whether ESL was used 
as monotherapy or adjunctive therapy, the rate of ESL discontinu‐
ation due to AEs was lower in patients treated with ESL monother‐
apy at the last visit, compared with those treated with adjunctive 
therapy at the last visit. This may therefore reflect an improvement 
in overall tolerability as patients withdrew from AED polytherapy 
to monotherapy (since the majority of patients treated with ESL 
monotherapy at the last visit had previously received concomi‐
tant AED treatment[s] prior to withdrawing to ESL monotherapy). 
This idea is supported by the results of the subanalysis of patients 
who received ESL as initial adjunctive therapy, since the rate of 
ESL discontinuation was significantly lower in patients who did 
versus did not withdraw to ESL monotherapy. These findings are 
consistent with those of a previous Euro‐Esli subanalysis, which 
demonstrated that the incidence of AEs leading to discontinuation 
(as well as the overall incidence of AEs) was significantly lower 
in patients treated with less than two concomitant AEDs than in 
those treated with two or more concomitant AEDs.8 In the current 
study, the most commonly reported AEs (dizziness, somnolence, 
instability/ataxia, fatigue) and AEs leading to discontinuation (diz‐
ziness and fatigue) were generally typical of those associated with 
sodium channel modulation (ESL’s primary mechanism of action) 
and consistent with ESL’s known safety profile.1,26 For example, in 
the phase III monotherapy trial conducted in patients with newly 
diagnosed	epilepsy,	the	most	frequently	reported	ESL‐related	AEs	
(≥5%	of	patients)	were	dizziness,	headache,	 somnolence,	and	 fa‐
tigue,	 and	 the	AEs	 that	most	 frequently	 led	 to	 ESL	 discontinua‐
tion	(≥1%	of	patients)	were	fatigue,	nausea,	dizziness,	somnolence,	
and rash.2 Combining drugs that block voltage‐dependent sodium 
channels is known to increase the likelihood of neurotoxic side 
effects (such as dizziness).26 Therefore, it is perhaps unsurprising 
that the incidence of AEs leading to discontinuation was higher 
when ESL was used as adjunctive therapy versus monotherapy, 
since sodium channel blocking is the most common mechanism of 
TA B L E  3   Summary of ESL dosing
ESL as initial 
monotherapy
ESL as monotherapy at last 
visit
ESL as initial adjunctive 
therapy
ESL as adjunctive 
therapy at last visit
Baseline
N 6 171 813 623
Mean (SD) dose, mg/day 800.0 (253.0) 499.4 (185.8) 527.0 (247.7) 515.3 (235.8)
Median (range) 800 (400‐1200) 400 (200‐1200) 400 (150‐1600) 400 (150‐1600)
3 months
N 17 165 910 650
Mean (SD) dose, mg/day 823.5 (299.0) 784.2 (216.4) 875.2 (271.2) 883.1 (266.0)
Median (range) 800 (400‐1600) 800 (400‐1600) 800 (400‐2000) 800 (400‐1600)
6 months
N 16 191 1002 770
Mean (SD) dose, mg/day 900.0 (230.9) 851.8 (264.5) 947.9 (293.2) 965.1 (292.6)
Median (range) 800 (800‐1600) 800 (400‐2400) 800 (200‐2800) 800 (200‐2800)
12 months
N 21 183 814 530
Mean (SD) dose, mg/day 895.2 (215.6) 862.3 (235.0) 1004.7 (307.2) 1022.6 (294.3)
Median (range) 800 (800‐1600) 800 (400‐1600) 800 (400‐2400) 1200 (400‐2400)
Last visit
N 50 227 1857 1099
Mean (SD) dose, mg/day 1000.0 (315.6) 878.9 (275.9) 977.2 (329.8) 962.2 (315.7)
Median (range) 800 (400‐1600) 800 (400‐2400) 800 (200‐2800) 800 (200‐2800)
Maximum dose
N 50 227 1857 1099
Mean (SD) dose, mg/day 1000.0 (315.6) 887.7 (266.6) 986.2 (327.2) 975.2 (313.8)
Median (range) 800 (400‐1600) 800 (400‐2400) 800 (300‐2800) 800 (300‐2800)
ESL, eslicarbazepine acetate; SD, standard deviation.
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F I G U R E  1   Responder and seizure 
freedom rates at 3 months, 6 months, 
12 months and the last visit for (A) 
patients who received ESL as initial 
monotherapy, (B) patients who received 
ESL as monotherapy at the last visit, 
(C) patients who received ESL as initial 
adjunctive therapy and (D) patients who 
received ESL as adjunctive therapy at 
the last visit. Response was defined as 
≥50%	seizure	frequency	reduction	from	
baseline. Seizure freedom was defined as 
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action among currently available AEDs.26 This is supported by a 
previously reported subanalysis of Euro‐Esli, which compared data 
from patients using other sodium channel blockers with those not 
using other sodium channel blockers.8 This found that the over‐
all incidence of AEs was similar between the groups, but the rate 
of discontinuation due to AEs was significantly higher in patients 
treated with other sodium channel blockers versus those who 
were not.8 Overall, no new or unexpected safety signals emerged 
in either the monotherapy or adjunctive therapy settings in the 
current study.
The findings of this study complement evidence from clinical 
trials, which have demonstrated that ESL is efficacious and gener‐
ally well tolerated when used as initial monotherapy in patients with 
newly diagnosed focal‐onset seizures,2 and when used in patients 
with uncontrolled focal‐onset seizures who have withdrawn to ESL 
monotherapy following treatment with other AEDs.3,4 In the current 
analysis, the seizure freedom rates at 6 months for patients treated 
with	ESL	as	monotherapy	at	the	last	visit	(72.2%)	and	those	who	with‐
drew	from	ESL	adjunctive	therapy	to	ESL	monotherapy	(72.8%)	were	
similar to the 26‐week seizure freedom rate observed in the phase 
III monotherapy trial conducted in patients with newly diagnosed 
epilepsy	 (71.1%).2 Moreover, the median ESL dose at 6 months in 
patients treated with ESL as monotherapy at the last visit (800 mg/
day) was the same as the target ESL dose achieved by the majority 
of patients in the phase III trial, and the rates of hyponatremia were 
also	comparable	(2.6%	in	the	current	analysis,	2.5%	in	the	phase	III	
trial).2 In the current analysis, the incidences of TEAEs and TEAEs 
leading to discontinuation were lower in patients treated with ESL as 
monotherapy	at	the	last	visit	(27.1%	and	4.8%,	respectively)	and	in	
those who withdrew from ESL adjunctive therapy to ESL monother‐
apy	 (28.6%	and	4.5%,	respectively)	 than	 in	those	treated	with	ESL	
monotherapy	in	the	phase	III	trial	(76.3%	and	14.0%,	respectively),2 
which is likely to reflect the more individualized approach to treat‐
ment adopted in clinical practice in comparison with clinical trials.
The overall seizure freedom rates for patients treated with ESL 
as	monotherapy	at	the	last	visit	(70.2%)	and	patients	who	withdrew	
from	 ESL	 adjunctive	 therapy	 to	 ESL	 monotherapy	 (71.7%)	 in	 the	
current analysis were substantially higher than the seizure free‐
dom rates observed in the phase III withdrawal to monotherapy 
trials conducted in patients with uncontrolled focal‐onset seizures 
(13.3%‐17.0%	during	last	4	weeks	of	monotherapy).3,4 Similarly, the 
overall responder rates for patients treated with ESL as monotherapy 
F I G U R E  2   Subanalysis of patients 
who received ESL as initial adjunctive 
therapy: responder rates (A) and seizure 
freedom rates (B) at 3 months, 6 months, 
12 months and the last visit for patients 
who withdrew to ESL monotherapy and 
those who received ESL as adjunctive 
therapy throughout follow‐up. Response 
was	defined	as	≥50%	seizure	frequency	
reduction from baseline. Seizure freedom 
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at	the	last	visit	(90.4%)	and	patients	who	withdrew	from	ESL	adjunc‐
tive	therapy	to	ESL	monotherapy	(92.9%)	in	the	current	analysis	were	
substantially higher than the responder rates observed in the phase 
III	withdrawal	to	monotherapy	trials	(32.2%‐46.0%	during	10‐week	
monotherapy treatment periods).3,4 These findings are perhaps un‐
surprising since the phase III withdrawal to monotherapy trials was 
conducted using a design in which baseline concomitant AEDs were 
down‐titrated and withdrawn regardless of patients’ prior response 
to treatment or clinical characteristics, and which therefore differed 
fundamentally from the individualized approach to treatment used 
in clinical practice (ie, as used in the studies included in Euro‐Esli). 
The similar seizure freedom rates observed in the current study and 
the phase III trial of ESL as initial monotherapy in patients with newly 
diagnosed focal‐onset seizures2 may nevertheless provide further 
evidence to suggest that the patients treated with ESL monotherapy 
in Euro‐Esli were likely to have mostly comprised newly diagnosed 
patients, rather than patients with more long‐standing, refractory 
focal epilepsy.
The findings of the study are also consistent with those of a re‐
cent multicenter, prospective, clinical practice study, conducted in 
17 hospitals in Spain, in which 117 patients with focal seizures, aged 
9‐87 years, were treated with ESL monotherapy.28 The responder 
rates	 (where	response	was	defined	as	≥50%	seizure	 frequency	re‐
duction)	 after	 3,	 6,	 and	12	months	were	82.0%,	 79.7%	83.0%,	 re‐
spectively28 (the corresponding responder rates in patients who 
received monotherapy at the last visit in the current study were 
83.0%,	90.7%,	and	93.2%,	respectively,	and	in	those	who	withdrew	
from ESL adjunctive therapy to ESL monotherapy, the correspond‐
ing	values	were	84.4%,	91.7%,	and	94.1%,	respectively).	AEs	were	
reported	 by	 15.3%	 of	 patients	 and	 those	 reported	 by	 more	 than	
one patient comprised instability and dizziness (n = 9), somnolence 
(n = 3), and mild hyponatremia (n = 3).28
It is difficult to directly compare the findings of the current anal‐
yses with those of studies that have assessed the effectiveness of 
monotherapy with other AEDs in clinical practice, primarily due to 
differences in study designs and patient populations. Some studies 
TA B L E  4   Summary of AEs and AEs leading to discontinuation
ESL as initial 
monotherapy
ESL as monotherapy at last 
visit
ESL as initial adjunctive 
therapy
ESL as adjunctive 
therapy at last visit
AEs
N 85 229 1933 1109
Patients	with	any	AE,	n	(%) 25 (29.4) 62 (27.1) 665 (34.4) 342 (30.8)
Most	frequently	reported	AEs,a	n	(%)
Dizziness 1 (1.2) 9 (3.9) 131 (6.8) 67 (6.0)
Somnolence 3 (3.5) 13 (5.7) 97 (5.0) 52 (4.7)
Instability/ataxia 7 (8.2) 1 (0.4) 59 (3.1) 17 (1.5)
Fatigue 2 (2.4) 5 (2.2) 103 (5.3) 39 (3.5)
AEs of special interestc
Hyponatremiad 0 6 (2.6) 68 (3.5) 28 (2.5)
Hyponatremia (sodium level 
<125	mEq/L)
0 0 15 (0.8) 7 (0.6)
Rash 1 (1.2) 0 43 (2.2) 25 (2.3)
AEs leading to discontinuation
N 82 228 1867 1096
Patients with any AE leading to 
discontinuation,	n	(%)
8 (9.8) 11 (4.8) 259 (13.9) 158 (14.4)
Most	frequently	reported	AEs	leading	to	discontinuation,b	n	(%)
Dizziness 0 (0.0) 1 (0.4) 46 (2.5) 29 (2.6)
Fatigue 1 (1.2) 0 38 (2.0) 14 (1.3)
AEs of special interest leading to discontinuationc
Hyponatremiad 0 2 (0.9) 19 (1.0) 12 (1.1)
Rash 1 (1.2) 0 29 (1.6) 21 (1.9)
AE, adverse event; ESL, eslicarbazepine acetate
a≥5%	of	patients	in	any	group.	
b≥2%	of	patients	in	any	group.	
cAny patients in any group. 
dAs reported by participating clinicians. Sodium levels were recorded for 52/68 patients reported as having hyponatremia; mean (SD) sodium level in 
these	52	patients	was	127.3	(4.5)	mEq/L	(median,	127.0;	range,	117‐137).	
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have reported outcomes for the use of monotherapy with another 
member of the dibenzazepine family of AEDs, oxcarbazepine, in the 
clinical practice setting.29,30 For example, in a retrospective evalua‐
tion	of	61	outpatients,	aged	≥16	years,	with	focal	or	generalized	epi‐
lepsy (simple or complex partial seizures, with or without secondary 
generalization, and generalized seizures induced by sleep) who were 
treated with oxcarbazepine in clinical practice in Italy, 12‐month 
seizure	 freedom	 rates	were	 76.9%	 in	 patients	 treated	with	 oxcar‐
bazepine	 monotherapy	 (n	=	52)	 and	 11.1%	 in	 those	 treated	 with	
oxcarbazepine as adjunctive therapy (n = 9).29 Furthermore, several 
studies have assessed the effectiveness of monotherapy with an‐
other sodium channel blocker, lacosamide, in clinical practice.31‐33 In 
a retrospective, non‐interventional chart review of 439 patients with 
focal	 seizures,	 aged	≥16	years,	who	were	 treated	with	 lacosamide	
monotherapy according to standard clinical practice in Italy, Spain, 
and	the	Netherlands,	6‐month	seizure	freedom	rates	were	66.3%	in	
patients	treated	with	lacosamide	as	initial	monotherapy	and	63.0%	
in those who converted to lacosamide monotherapy from another 
AED, and the corresponding 12‐month seizure freedom rates were 
60.2%	and	52.5%,	respectively.31 Even considering the limited com‐
parability of these studies to the current data, ESL seems to be at 
least as effective as other sodium channel blockers.
The current analyses were limited because the monotherapy 
and adjunctive therapy subgroups were not “pure” throughout the 
duration of follow‐up, since some patients initially treated with 
monotherapy or adjunctive therapy converted to adjunctive ther‐
apy or monotherapy, respectively, during the course of the study, 
but were included in the subgroup to which they were initially al‐
located for the purposes of “initial treatment” analyses. Similarly, 
some of the patients treated with monotherapy and adjunctive 
therapy at the last visit were previously treated with adjunctive 
therapy and monotherapy, respectively, but were included in the 
subgroup that applied to them at the last visit (ie, monotherapy or 
adjunctive therapy) for all the “treatment at last visit” analyses. 
These limitations are, however, vindicated by the results of the su‐
banalysis of patients treated initially with ESL adjunctive therapy 
who	did	and	did	not	subsequently	withdraw	to	ESL	monotherapy,	
since these were consistent with the other findings of the study. 
As with the overall Euro‐Esli study,8 the study has additional lim‐
itations, primarily because it was a subanalysis of a retrospective 
pooled analysis. Moreover, there was great heterogeneity in the 
studies included in Euro‐Esli, and although individual patient data 
were previously reviewed by the authors of the individual studies, 
they were not reviewed systematically post hoc.8 The heteroge‐
neous nature of the studies included in Euro‐Esli also meant that, 
across all endpoints and assessments, data were not available for 
all patients at all timepoints. However, the large number of pa‐
tients included in Euro‐Esli allowed a meaningful number of pa‐
tients to be assessed in the current analysis, mitigating some of 
these limitations.
In summary, taking into account the aforementioned limita‐
tions, these findings provide further evidence supporting the 
use of ESL as monotherapy, as well as adjunctive therapy, for 
focal‐onset seizures, complementing evidence from regulatory 
clinical trials.
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